Section Arrow
Quote
BCTX.NASDAQ
- Briacell Therapeutics Corp NEW
Quotes are at least 15-min delayed:2025/07/20 18:34 EDT
Regular Hours
Last
 0.7983
-0.0331 (-3.98%)
Day High 
0.8324 
Prev. Close
0.8314 
1-M High
3.16 
Volume 
1.56M 
Bid
0.81
Ask
0.8159
Day Low
0.7855 
Open
0.81 
1-M Low
0.69 
Market Cap 
5.63M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.94 
20-SMA 2.46 
50-SMA 2.95 
52-W High 29.4 
52-W Low 0.69 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.69/-1.77
Enterprise Value
5.66M
Balance Sheet
Book Value Per Share
1.83
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed：2025/07/20 18:34 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.